MOLECULES OF THE MILLENNIUM
Year : 2015  |  Volume : 6  |  Issue : 2  |  Page : 118-121

Suvorexant: The first orexin receptor antagonist to treat insomnia


Department of Pharmacology, School of Medical Sciences and Research, Greater Noida, Uttar Pradesh, India

Correspondence Address:
Ashok K Dubey
Department of Pharmacology, School of Medical Sciences and Research, Greater Noida - 201 306, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-500X.155496

Rights and Permissions

Primary insomnia is mainly treated with drugs acting on benzodiazepine receptors and a few other classes of drugs used for different co-morbidities. A novel approach to treat insomnia has been introduced recently, with the approval of suvorexant, the first in a new class of orexin receptor antagonists. Orexin receptors in the brain have been found to play an important role in the regulation of various aspects of arousal and motivation. The drugs commonly used for insomnia therapy to date, have often been associated with adverse effects, such as, day-time somnolence, amnesia, confusion, and gait disturbance, apart from the risk of dependence on chronic use. Suvorexant has not shown these adverse effects because of its unique mechanism of action. It also appears to be suitable as a chronic therapy for insomnia, because of minimal physical dependence. The availability of this new drug as an effective and safe alternative is an important and welcome development in insomnia management.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3742    
    Printed39    
    Emailed1    
    PDF Downloaded785    
    Comments [Add]    
    Cited by others 14    

Recommend this journal